Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | PTGIR | P43119 | 11/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 10/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276278 | 0.97 | CNR2 (0.38) | CNR2PTGIRTBXA2RKDM4EALDH1A1 | |
| SCHEMBL6276906 | 0.94 | PTGIR (0.39) | CNR2PTGIRTBXA2RKDM4EALDH1A1 | |
| SCHEMBL6276743 | 0.87 | CNR2 (0.41) | CNR2 | |
| SCHEMBL6275403 | 0.86 | CNR2 (0.40) | CNR2KDM4EALDH1A1 | |
| SCHEMBL6273134 | 0.85 | NQO1 (0.38) | KDM4EALDH1A1HPGDGLAL3MBTL1 | |
| SCHEMBL6277696 | 0.85 | ALDH1A1 (0.40) | PTGIRTBXA2RKDM4EALDH1A1HPGD | |
| SCHEMBL6277228 | 0.84 | CNR2 (0.45) | CNR2PTGIRTBXA2RKDM4EALDH1A1 | |
| SCHEMBL6276067 | 0.84 | CNR2 (0.40) | CNR2 | |
| SCHEMBL6271658 | 0.83 | CNR2 (0.42) | CNR2PTGIRTBXA2RKDM4EALDH1A1 | |
| SCHEMBL6277151 | 0.83 | ALDH1A1 (0.43) | PTGIRTBXA2RKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273578-B1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK & CHEMICALS (JP) | 2005-02-23 | — | — | EP | disclosed |
| US-6670391-B2 | For inhibiting both immediate and delayed type allergic reactions; side effect reduction | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1273578-A1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | HRH2, HRH1, HRH4 | CNR2 249/4885PTGIR 316/4885TBXA2R 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.